Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies

Current Neuropharmacology

Volumn 8, Issue 3, 2010, Pages 243-253

  Idris, Aymen I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anabolic; Anti resorptive; Bone; Cannabinoid; CB1; CB2; GPR55; Osteoporosis; Rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANABOLIC AGENT; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; SCH 036; UNCLASSIFIED DRUG;

ADIPOGENESIS; ARTICLE; BONE MASS; BONE REMODELING; BONE TURNOVER; BRAIN NERVE CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 78549260389     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015910792246173     Document Type: Article

References (125)

1. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov., 2008, 7, 438-455.
2. Klein, T.W., Lane, B., Newton, C.A., Friedman, H. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med., 2000, 225, 1-8.
3. Grant, I. Cahn, B.R. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clin. Neurosci. Res., 2005, 5, 185-199.
4. Pertwee, R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol., 2005, 1-51.
5. Ross, R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol., 2003, 140, 790-801.
6. Di Marzo, V., De, P.L., Fezza, F., Ligresti, A., Bisogno, T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66, 377-391.
7. van der Stelt, M. Di Marzo, V. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat., 2005, 77, 111-122.
8. Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., Sugiura, T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett., 1998, 429, 152-156.
9. Stella, N., Schweitzer, P., Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature, 1997, 388, 773-778.
10. Felder, C.C., Briley, E.M., Axelrod, J., Simpson, J.T., Mackie, K., Devane, W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 1993, 90, 7656-7660.
11. Felder, C.C., Nielsen, A., Briley, E.M., Palkovits, M., Priller, J., Axelrod, J., Nguyen, D.N., Richardson, J.M., Riggin, R.M., Koppel, G.A., Paul, S.M., Becker, G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett., 1996, 393, 231-235.
12. Tam, J., Trembovler, V., Di, M., V, Petrosino, S., Leo, G., Alexandrovich, A., Regev, E., Casap, N., Shteyer, A., Ledent, C., Karsak, M., Zimmer, A., Mechoulam, R., Yirmiya, R., Shohami, E., Bab, I. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J., 2008, 22, 285-294.
13. Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S.R., McCallion, D., Pertwee, R., Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem., 1999, 42, 769-776.
14. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J.P., Le Fur, G., Casellas, P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem., 1997, 272, 22330-22339.
15. Gatley, S.J., Gifford, A.N., Volkow, N.D., Lan, R., Makriyannis, A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol., 1996, 307, 331-338.
16. Gatley, S.J., Lan, R., Pyatt, B., Gifford, A.N., Volkow, N.D., Makriyannis, A. Binding of the non-classical cannabinoid CP 55, 940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci., 1997, 61, L-7.
17. Hosohata, Y., Quock, R.M., Hosohata, K., Makriyannis, A., Consroe, P., Roeske, W.R., Yamamura, H.I. AM630 antagonism of cannabinoid-stimulated [35S] GTP gamma S binding in the mouse brain. Eur. J. Pharmacol., 1997, 321, R1-R3.
18. Hosohata, K., Quock, R.M., Hosohata, Y., Burkey, T.H., Makriyannis, A., Consroe, P., Roeske, W.R., Yamamura, H.I. AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci., 1997, 61, L115-L118.
19. Landsman, R.S., Makriyannis, A., Deng, H., Consroe, P., Roeske, W.R., Yamamura, H.I. AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci., 1998, 62, L109-L113.
20. Ross, R.A., Brockie, H.C., Stevenson, L.A., Murphy, V.L., Templeton, F., Makriyannis, A., Pertwee, R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol., 1999, 126, 665-672.
21. Meschler, J.P., Kraichely, D.M., Wilken, G.H., Howlett, A.C. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl) -1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem. Pharmacol., 2000, 60, 1315-1323.
22. Pertwee, R.G. Ross, R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66, 101-121.
23. Maccarrone, M., Finazzi-Agro, A. Endocannabinoids and their actions. Vitam. Horm., 2002, 65, 225-255.
24. Sanchez, M.G., Ruiz-Llorente, L., Sanchez, A.M., Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal., 2003, 15, 851-859.
25. Guzman, M., Galve-Roperh, I., Sanchez, C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci., 2001, 22, 19-22.
26. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 1997, 74, 129-180.
27. Di Marzo, V., Bifulco, M., De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov., 2004, 3, 771-784.
28. Howlett, A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol., 2005, 53-79.
29. Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G., Casellas, P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem., 1993, 214, 173-180.
30. Klein, T.W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., Friedman, H. The cannabinoid system and immune modulation. J. Leukoc. Biol., 2003, 74, 486-496.
31. Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., Mechoulam, R., Zimmer, A., Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA, 2006, 103, 696-701.
32. Idris, A.I., Van 't Hof, R.J., Greig, I.R., Ridge, S.A., Baker, D., Ross, R.A., & Ralston, S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med., 2005, 11, 774-779.
33. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152, 1092-1101.
34. Begg, M., Pacher, P., Batkai, S., Osei-Hyiaman, D., Offertaler, L., Mo, F.M., Liu, J., Kunos, G. Evidence for novel cannabinoid receptors. Pharmacol. Ther., 2005, 106, 133-145.
35. Sawzdargo, M., Nguyen, T., Lee, D.K., Lynch, K.R., Cheng, R., Heng, H.H., George, S.R., O'Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res., 1999, 64, 193-198.
36. Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Chambers, J.K., Randall, A.D., Davis, J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 2000, 129, 227-230.
37. Teitelbaum, S.L. Bone resorption by osteoclasts. Science, 2000, 289, 1504-1508.
38. Manolagas, S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 2000, 21, 115-137.
39. Suda, T., Nakamura, I., Jimi, E., Takahashi, N. Regulation of osteoclast function. J. Bone Miner. Res., 1997, 12, 869-879.
40. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 1998, 95, 3597-3602.
41. Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R, Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.X., Kaufman, S., Sarosi, I., Shalhoub, V, Senaldi, G., Guo, J., Delaney, J., Boyle, W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93, 165-176.
42. Sarma, U. Flanagan, A.M. Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood, 1996, 88, 2531-2540.
43. Suda, T., Ueno, Y., Fujii, K., Shinki, T. Vitamin D and bone. J. Cell Biochem., 2003, 88, 259-266.
44. Lee, S.K. Lorenzo, J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology, 1999, 140, 3552-3561.
45. Weinstein, R.S. Manolagas, S.C. Apoptosis and osteoporosis. Am. J. Med., 2000, 108, 153-164.
46. Ducy, P., Schinke, T., Karsenty, G. The osteoblast: a sophisticated fibroblast under central surveillance. Science, 2000, 289, 1501-1504.
47. Bonewald, L.F. Dallas, S.L. Role of active and latent transforming growth factor beta in bone formation. J. Cell Biochem., 1994, 55, 350-357.
48. Partridge, N.C., Walling, H.W., Bloch, S.R., Omura, T.H., Chan, P.T., Pearman, A.T., Chou, W.Y. The regulation and regulatory role of collagenase in bone. Crit. Rev. Eukaryot. Gene Expr., 1996, 6, 15-27.
49. Jilka, R.L., Weinstein, R.S., Bellido, T., Parfitt, A.M., Manolagas, S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res., 1998, 13, 793-802.
50. Nefussi, J.R., Sautier, J.M., Nicolas, V., Forest, N. How osteoblasts become osteocytes: a decreasing matrix forming process. J. Biol. Buccale, 1991, 19, 75-82.
51. Raisz, L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest., 2005, 115, 3318-3325.
52. Melton, L.J., III. Adverse outcomes of osteoporotic fractures in the general population. J. Bone Miner. Res., 2003, 18, 1139-1141.
53. Center, J.R., Nguyen, T.V., Schneider, D., Sambrook, P.N., Eisman, J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 1999, 353, 878-882.
54. Amin, S. Male osteoporosis: epidemiology and pathophysiology. Curr. Osteoporos. Rep., 2003, 1, 71-77.
55. Ismail, A.A., O'Neill, T.W., Cooper, C., Finn, J.D., Bhalla, A.K., Cannata, J.B., Delmas, P., Falch, J.A., Felsch, B., Hoszowski, K., Johnell, O., Diaz-Lopez, J.B., Lopez, V.A., Marchand, F., Raspe, H., Reid, D.M., Todd, C., Weber, K., Woolf, A., Reeve, J., Silman, A.J. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos. Int., 1998, 8, 291-297.
56. Kannus, P., Parkkari, J., Sievanen, H., Heinonen, A., Vuori, I., Jarvinen, M. Epidemiology of hip fractures. Bone, 1996, 18, 57S-63S.
57. Kanis, J., Johnell, O., Gullberg, B., Allander, E., Elffors, L., Ranstam, J., Dequeker, J., Dilsen, G., Gennari, C., Vaz, A.L., Lyritis, G., Mazzuoli, G., Miravet, L., Passeri, M., Perez, C.R., Rapado, A., Ribot, C. Risk factors for hip fracture in men from southern Europe: the MEDOS study. mediterranean osteoporosisstudy. Osteoporos. Int., 1999, 9, 45-54.
58. Kaufman, J.M., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., Sedrine, W.B., Calvo, G., Devogelaer, J.P., Fuchs, V., Kreutz, G., Nilsson, P., Pols, H., Ringe, J., Van Haelst, L., Reginster, J.Y. Background for studies on the treatment of male osteoporosis: state of the art. Ann. Rheum. Dis., 2000, 59, 765-772.
59. Melton, L.J., III, Gabriel, S.E., Crowson, C.S., Tosteson, A.N., Johnell, O., Kanis, J.A. Cost-equivalence of different osteoporotic fractures. Osteoporos. Int., 2003, 14, 383-388.
60. Riggs, B.L. Melton, L.J., III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone, 1995, 17, 505S-511S.
61. Riggs, B.L., Wahner, H.W., Seeman, E., Offord, K.P., Dunn, W.L., Mazess, R.B., Johnson, K.A., Melton, L.J., III. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J. Clin. Invest., 1982, 70, 716-723.
62. Weinstein, R.S. Manolagas, S.C. Apoptosis and osteoporosis. Am. J. Med., 2000, 108, 153-164.
63. Kameda, T., Mano, H., Yuasa, T., Mori, Y., Miyazawa, K., Shiokawa, M., Nakamaru, Y., Hiroi, E., Hiura, K., Kameda, A., Yang, N.N., Hakeda, Y., Kumegawa, M. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med., 1997, 186, 489-495.
64. Bord, S., Ireland, D.C., Beavan, S.R., Compston, J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone, 2003, 32, 136-141.
65. Eriksen, E.F., Mosekilde, L., Melsen, F. Trabecular bone resorption depth decreases with age: differences between normal males and females. Bone, 1985, 6, 141-146.
66. Gimble, J.M., Zvonic, S., Floyd, Z.E., Kassem, M., Nuttall, M.E. Playing with bone and fat. J. Cell Biochem., 2006, 98, 251-266.
67. Lips, P., Courpron, P., Meunier, P.J. Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif. Tissue Res., 1978, 26, 13-17.
68. Patschan, D., Loddenkemper, K., Buttgereit, F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone, 2001, 29, 498-505.
69. Delany, A.M., Gabbitas, B.Y., Canalis, E. Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J Cell Biochem., 1995, 57, 488-494.
70. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature, 2003, 423, 356-361.
71. Green, M.J., Deodhar, A.A. Bone changes in early rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol., 2001, 15, 105-123.
72. Coleman, R.E. Skeletal complications of malignancy. Cancer, 1997, 80, 1588-1594.
73. Amling, M., Pogoda, P., Beil, F.T., Schilling, A.F., Holzmann, T., Priemel, M., Blicharski, D., Catala-Lehnen, P., Rueger, J.M., Ducy, P., Karsenty, G. Central control of bone mass: brainstorming of the skeleton. Adv. Exp. Med. Biol., 2001, 496, 85-94.
74. Patel, M.S. Elefteriou, F. The new field of neuroskeletal biology. Calcif. Tissue Int., 2007, 80, 337-347.
75. Skerry, T.M. Genever, P.G. Glutamate signalling in non-neuronal tissues. Trends Pharmacol. Sci., 2001, 22, 174-181.
76. van't Hof, R.J. Ralston, S.H. Nitric oxide and bone. Immunology, 2001, 103, 255-261.
77. van't Hof, R.J., Macphee, J., Libouban, H., Helfrich, M.H., Ralston, S.H. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology, 2004, 145, 5068-5074.
78. Abe, E., Marians, R.C., Yu, W., Wu, X.B., Ando, T., Li, Y., Iqbal, J., Eldeiry, L., Rajendren, G., Blair, H.C., Davies, T.F., Zaidi, M. TSH is a negative regulator of skeletal remodeling. Cell, 2003, 115, 151-162.
79. Sun, L., Peng, Y., Sharrow, A.C., Iqbal, J., Zhang, Z., Papachristou, D.J., Zaidi, S., Zhu, L.L., Yaroslavskiy, B.B., Zhou, H., Zallone, A., Sairam, M.R., Kumar, T.R., Bo, W., Braun, J., Cardoso-Landa, L., Schaffler, M.B., Moonga, B.S., Blair, H.C., Zaidi, M. FSH directly regulates bone mass. Cell, 2006, 125, 247-260.
80. Chenu, C. Marenzana, M. Sympathetic nervous system and bone remodeling. Joint Bone Spine, 2005, 72, 481-483.
81. Cherruau, M., Facchinetti, P., Baroukh, B., Saffar, J.L. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone, 1999, 25, 545-551.
82. Sisask, G., Bjurholm, A., Ahmed, M., Kreicbergs, A. The development of autonomic innervation in bone and joints of the rat. J. Auton. Nerv. Syst., 1996, 59, 27-33.
83. Serre, C.M., Farlay, D., Delmas, P.D., Chenu, C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone, 1999, 25, 623-629.
84. Cherruau, M., Facchinetti, P., Baroukh, B., Saffar, J.L. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone, 1999, 25, 545-551.
85. Kondo, H., Nifuji, A., Takeda, S., Ezura, Y., Rittling, S.R., Denhardt, D.T., Nakashima, K., Karsenty, G., Noda, M. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J. Biol. Chem., 2005, 280, 30192-30200.
86. Benarroch, E.E. Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology, 2009, 72, 1016-1020.
87. Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A.F., Beil, F.T., Shen, J., Vinson, C., Rueger, J.M., Karsenty, G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell, 2000, 100, 197-207.
88. Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K.L., Armstrong, D., Ducy, P., Karsenty, G. Leptin regulates bone formation via the sympathetic nervous system. Cell, 2002, 111, 305-317.
89. Elefteriou, F., Ahn, J.D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo, H., Richards, W.G., Bannon, T.W., Noda, M., Clement, K., Vaisse, C., Karsenty, G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature, 2005, 434, 514-520.
90. Swarthout, J.T., D'Alonzo, R.C., Selvamurugan, N., Partridge, N.C. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene, 2002, 282, 1-17.
91. Bab, I., Ofek, O., Tam, J., Rehnelt, J., Zimmer, A. Endocannabinoids and the regulation of bone metabolism. J. Neuroendocrinol., 2008, 20(Suppl 1), 69-74.
92. Ridge SA, Ford L, Cameron GA, Ross RA, Rogers MJ. Endocannabinoids are produced by bone cells and stimulate bone resorption in vitro. Calcif. Tissue Int., 2007, S120.
93. Sophocleous, A., Landao-Bassonga, E., van't Hof, R., Ralston, S.H., Idris, A.I. The type 2 cannabinoid receptor s (CB2) protects against age-related bone loss by affecting bone formation and CB2 agonists exhibit anabolic activity. Bone, 2009, 44(2), S219.
94. Tam, J., Ofek, O., Fride, E., Ledent, C., Gabet, Y., Muller, R., Zimmer, A., Mackie, K., Mechoulam, R., Shohami, E., Bab, I. Involvement of Neuronal Cannabinoid Receptor, CB1, in Regulation of Bone Mass and Bone Remodeling. Mol. Pharmacol., 2006, 70, 786-792.
95. Idris, A.I., Sophocleous, A., Landao-Bassonga, E., Canals, M., Milligan, G., Baker, D., van't Hof, R.J., Ralston, S.H. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab., 2009, 10, 139-147.
96. Rossi, F., Siniscalco, D., Luongo, L., De Petrocellis, L., Bellini, G., Petrosino, S., Torella, M., Santoro, C., Nobili, B., Perrotta, S., Di, M., V, Maione, S. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009, 44, 476-484.
97. Nong, L., Newton, C., Friedman, H., Klein, T.W. CB1 and CB2 Receptor mRNA Expression in Human Peripheral Blood Mononuclear Cells (PBMC) from Various Donor Types. In Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases. 2001, pp. 229-233.
98. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232, 54-61.
99. Scutt, A. Williamson, E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif. Tissue Int., 2007, 80, 50-59.
100. Palazuelos, J., Davoust, N., Julien, B., Hatterer, E., Aguado, T., Mechoulam, R., Benito, C., Romero, J., Silva, A., Guzman, M., Nataf, S., & Galve-Roperh, I. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem., 2008, 283, 13320-13329.
101. Saunders, C.I., Kunde, D.A., Crawford, A., Geraghty, D.P. Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol. Immunol., 2007, 44, 1429-1435.
102. Abed, E., Labelle, D., Martineau, C., Loghin, A., Moreau, R. Expression of transient receptor potential (TRP) channels in human and murine osteoblast-like cells. Mol. Membr. Biol., 2009, 26, 146-158.
103. Chestnut, C.H., III Calcitonin in the prevention and treatment of osteoporosis. Osteoporos. Int., 1993, 3(Suppl 1), 206-207.
104. Coleman, R.E. Risks and benefits of bisphosphonates. Br. J. Cancer, 2008, 98, 1736-1740.
105. Chow, J.W.M. Ovariectomy and estrogen replacement in rodents. In Bone Research Protocols (Helfrich, M.H., Ralston, S.H., Eds), Humana Press, Totowa, 2004, pp. 361-365.
106. Idris, A.I., Sophocleous, A., Landao-Bassonga, E., van't Hof, R.J., Ralston, S.H. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology, 2008, 149, 5619-5626.
107. Whyte, L.S., Ryberg, E., Sims, N.A., Ridge, S.A., Mackie, K., Greasley, P.J., Ross, R.A., Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. USA, 2009, 106, 16511-16516.
108. Brown, A.J. Novel cannabinoid receptors. Br. J. Pharmacol., 2007, 152, 567-575.
109. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152, 1092-1101.
110. Lunn, C.A., Fine, J., Rojas-Triana, A., Jackson, J.V., Lavey, B., Kozlowski, J.A., Hipkin, R.W., Lundell, D.J., Bober, L. Cannabinoid CB(2)-selective inverse agonist protects against antigeninduced bone loss. Immunopharmacol. Immunotoxicol., 2007, 29, 387-401.
111. Idris, A.I., Landao-Bassonga, E., Ralston, S. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone, 2010, 46, 1089-1099.
112. De Petrocellis, L., Bisogno, T., Davis, J.B., Pertwee, R.G., Di, M., V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett., 2000, 483, 52-56.
113. Hermann, H., De Petrocellis, L., Bisogno, T., Schiano, M.A., Lutz, B., Di, M. V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol. Life Sci., 2003, 60, 607-616.
114. Ahluwalia, J., Urban, L., Bevan, S., Nagy, I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci., 2003, 17, 2611-2618.
115. Rossi, F., Siniscalco, D., Luongo, L., De Petrocellis, L., Bellini, G., Petrosino, S., Torella, M., Santoro, C., Nobili, B., Perrotta, S., Di, M., V, Maione, S. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009, 44, 476-484.
116. George, K.L., Saltman, L.H., Stein, G.S., Lian, J.B., Zurier, R.B. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J. Cell Physiol., 2008, 214, 714-720.
117. Canalis, E., Giustina, A., Bilezikian, J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J Med., 2007, 357, 905-916.
118. Ravinet, T.C., Delgorge, C., Menet, C., Arnone, M., Soubrie, P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord., 2004, 28, 640-648.
119. Scutt, A. Williamson, E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif. Tissue Int., 2007, 80, 50-59.
120. Karsak, M., Cohen-Solal, M., Freudenberg, J., Ostertag, A., Morieux, C., Kornak, U., Essig, J., Erxlebe, E., Bab, I., Kubisch, C., de Vernejoul, M.C., Zimmer, A. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet., 2005, 14, 3389-3396.
121. Yamada, Y., Ando, F., Shimokata, H. Association of candidate gene polymorphisms with bone mineral density in community dwelling Japanese women and men. Int. J. Mol. Med., 2007, 19, 791-801.
122. Bab, I., Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Br. J. Pharmacol., 2008, 153, 182-188.
123. Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Le Fur, G., Casellas, P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol., 2005, 517, 174-181.
124. Burstein, S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci., 2005, 77, 1674-1684.
125. © (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol., 2006, 69, 471-478.